So VeriSign's still-low invested capital supports its high current ROIC. On an adjusted basis, the company's ROIC was 4.4% for 2023, with a five-year average of 3.9%, according to the data provided by ...
HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...
In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...
J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...
Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...
CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...
On Sunday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced multiple program updates, including: In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor ...
Silver tends to outperform the rest of the precious metals sector close to the end of a given rally. We’re not there YET.
Commodities Analysis by Sunshine Profits (Przemyslaw Radomski, CFA) covering: Gold Spot US Dollar, Silver Spot US Dollar, ...
The stock market indexes surged on a tame CPI inflation report, reclaiming key levels. Tesla, Meta led a slew of new buys. Entrepreneur Advocates for a Healthier Future by Supporting Small ...